)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Revance Therapeutics (RVNC) investor relations material
Revance Therapeutics Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary7 Nov, 2024
Executive summary
Q3 2024 revenue was $59.9 million, up 11% year-over-year, driven by increased DAXXIFY and RHA® Collection sales.
Net loss from continuing operations for Q3 2024 was $38.1 million, compared to $39.4 million in Q3 2023; total net loss including discontinued operations was $141.2 million.
The company completed the exit of its Fintech Platform business, now classified as discontinued operations, resulting in $101.7 million in Q3 2024 net loss from discontinued operations.
A pending merger with Crown Laboratories is in process, with a tender offer at $6.66 per share; the deadline was extended to November 12, 2024, and closing is subject to customary conditions.
Management has concluded there is substantial doubt about the company's ability to continue as a going concern due to insufficient liquidity to fund operations for 12 months.
Financial highlights
Q3 2024 product revenue: $58.8 million (up 9% year-over-year); nine-month product revenue: $175.9 million (up 14%).
DAXXIFY Q3 2024 revenue: $28.3 million (up 29%); RHA® Collection Q3 2024 revenue: $30.5 million (down 5%).
Operating expenses for Q3 2024 were $92.1 million, flat year-over-year; SG&A expenses were $62.6 million, down from $65.8 million, including $7.3 million in merger-related costs.
Cash, cash equivalents, and short-term investments as of September 30, 2024: $184.1 million, down from $253.9 million at year-end 2023.
Net loss per share from continuing operations for Q3 2024 was $0.37; total net loss per share was $1.63.
Outlook and guidance
Management expects continued operating losses and negative cash flows for the foreseeable future.
Existing cash and investments are not sufficient to fund operations for at least 12 months; additional financing or cost reductions may be required.
All previously provided 2024 financial guidance was withdrawn and no forward-looking outlook will be provided due to the proposed merger.
The pending merger with Crown Laboratories, if completed, will result in the company becoming a wholly owned subsidiary and delisting from Nasdaq.
Why was the 2024 financial guidance withdrawn?
Assess impact of Fosun's DAXXIFY approval in China.
Explain the terms of the Teoxane ANZ agreement.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Revance Therapeutics Inc. is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic treatments. The company’s portfolio includes Daxxify, a long-lasting botulinum toxin for wrinkle reduction, and other injectable products for aesthetic enhancements. Revance also develops treatments targeting neurological and musculoskeletal disorders. Revance Therapeutics is headquartered in Nashville, Tennessee, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage